US Personalized Cancer Genome Sequencing Market Outlook 2018
The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing.
Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market’s growth potential for personalized cancer WGS till 2018.
The said advanced technology has potential to revolutionize the field of medicine. We have closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.
The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.
Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market’s growth potential for personalized cancer WGS till 2018.
The said advanced technology has potential to revolutionize the field of medicine. We have closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.
The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GENOME SEQUENCING: AN INTRODUCTION
4. CANCER STATISTICS BY DEMOGRAPHICS
4.1 Prevalence, Incidences, and Mortality (2010-2018)
4.2 Leading States by Incidence
4.3 Leading Cancers by Incidence
4.3.1 Male Cancer Incidences
4.3.2 Female Cancer Incidences
4.3.3 Age-Group
5. US PERSONALIZED CANCER WGS POTENTIAL MARKET TO 2018
6. US PERSONALIZED CANCER WGS: CURRENT AND FUTURE MARKET ANALYSIS
7. REGULATORY INSIGHTS
7.1 Clinical Laboratory Improvement Amendments (CLIA) Accreditation
7.2 CAP Accreditation
8. MARKET CONSTRAINTS
9. COMPETITIVE ASSESSMENT
9.1 Illumina
9.1.1 Business Overview
9.1.2 Key Information
9.1.3 Strengths and Weaknesses
9.2 Complete Genomics
9.2.1 Business Overview
9.2.2 Key Information
9.2.3 Strengths and Weaknesses
9.3 Beckman Coulter Genomics
9.3.1 Business Overview
9.3.2 Key Information
9.3.3 Strengths and Weaknesses
9.4 Expression Analysis
9.4.1 Business Overview
9.4.2 Key Information
9.4.3 Strengths and Weaknesses
9.5 EdgeBio
9.5.1 Business Overview
9.5.2 Key Information
9.5.3 Strengths and Weaknesses
9.6 Foundation Medicine
9.6.1 Business Overview
9.6.2 Key Information
9.6.3 Strengths and Weaknesses
9.7 SeqWright
9.7.1 Business Overview
9.7.2 Key Information
9.7.3 Strengths and Weaknesses
9.8 Ambry Genetics
9.8.1 Business Overview
9.8.2 Key Information
9.8.3 Strengths and Weaknesses
9.9 BGI Americas Corporation
9.9.1 Business Overview
9.9.2 Key Information
9.9.3 Strengths and Weaknesses
9.10 Cofactor Genomics
9.10.1 Business Overview
9.10.2 Key Information
9.10.3 Strengths and Weaknesses
2. RESEARCH METHODOLOGY
3. GENOME SEQUENCING: AN INTRODUCTION
4. CANCER STATISTICS BY DEMOGRAPHICS
4.1 Prevalence, Incidences, and Mortality (2010-2018)
4.2 Leading States by Incidence
4.3 Leading Cancers by Incidence
4.3.1 Male Cancer Incidences
4.3.2 Female Cancer Incidences
4.3.3 Age-Group
5. US PERSONALIZED CANCER WGS POTENTIAL MARKET TO 2018
6. US PERSONALIZED CANCER WGS: CURRENT AND FUTURE MARKET ANALYSIS
7. REGULATORY INSIGHTS
7.1 Clinical Laboratory Improvement Amendments (CLIA) Accreditation
7.2 CAP Accreditation
8. MARKET CONSTRAINTS
9. COMPETITIVE ASSESSMENT
9.1 Illumina
9.1.1 Business Overview
9.1.2 Key Information
9.1.3 Strengths and Weaknesses
9.2 Complete Genomics
9.2.1 Business Overview
9.2.2 Key Information
9.2.3 Strengths and Weaknesses
9.3 Beckman Coulter Genomics
9.3.1 Business Overview
9.3.2 Key Information
9.3.3 Strengths and Weaknesses
9.4 Expression Analysis
9.4.1 Business Overview
9.4.2 Key Information
9.4.3 Strengths and Weaknesses
9.5 EdgeBio
9.5.1 Business Overview
9.5.2 Key Information
9.5.3 Strengths and Weaknesses
9.6 Foundation Medicine
9.6.1 Business Overview
9.6.2 Key Information
9.6.3 Strengths and Weaknesses
9.7 SeqWright
9.7.1 Business Overview
9.7.2 Key Information
9.7.3 Strengths and Weaknesses
9.8 Ambry Genetics
9.8.1 Business Overview
9.8.2 Key Information
9.8.3 Strengths and Weaknesses
9.9 BGI Americas Corporation
9.9.1 Business Overview
9.9.2 Key Information
9.9.3 Strengths and Weaknesses
9.10 Cofactor Genomics
9.10.1 Business Overview
9.10.2 Key Information
9.10.3 Strengths and Weaknesses
LIST OF FIGURES:
Figure 3-1: Schematic Diagram of Sequencing used for Human Genome Project
Figure 3-2: Long-range Sequence Assembly in Whole Genome Shotgun Sequencing
Figure 4-1: Cancer Prevalence (Million), 2010-2018
Figure 4-2: Cancer Incidences (Million), 2010-2018
Figure 4-3: Cancer Mortality (‘000), 2010-2018
Figure 4-4: Incidences by Type of Cancer (%), 2014
Figure 4-5: Cancer Incidences by Age Group (%), 2010
Figure 5-1: Number of People earning > US$ 100K (2009-2012)
Figure 5-2: Potential Customers for Personalized Cancer WGS Market (Billion), 2013-2018
Figure 5-3: Potential Customers for Personalized Cancer WGS Market by Age-Group (%), 2014
Figure 5-4: Potential Market for Personalized Cancer WGS (Billion US$), 2013-2018
Figure 6-1: Tapped and Untapped Personalized Cancer WGS Market (%), 2014
Figure 6-2: Personalized Cancer WGS Market (Million US$), 2013-2018
Figure 3-1: Schematic Diagram of Sequencing used for Human Genome Project
Figure 3-2: Long-range Sequence Assembly in Whole Genome Shotgun Sequencing
Figure 4-1: Cancer Prevalence (Million), 2010-2018
Figure 4-2: Cancer Incidences (Million), 2010-2018
Figure 4-3: Cancer Mortality (‘000), 2010-2018
Figure 4-4: Incidences by Type of Cancer (%), 2014
Figure 4-5: Cancer Incidences by Age Group (%), 2010
Figure 5-1: Number of People earning > US$ 100K (2009-2012)
Figure 5-2: Potential Customers for Personalized Cancer WGS Market (Billion), 2013-2018
Figure 5-3: Potential Customers for Personalized Cancer WGS Market by Age-Group (%), 2014
Figure 5-4: Potential Market for Personalized Cancer WGS (Billion US$), 2013-2018
Figure 6-1: Tapped and Untapped Personalized Cancer WGS Market (%), 2014
Figure 6-2: Personalized Cancer WGS Market (Million US$), 2013-2018
LIST OF TABLES:
Table 4-1: Top Ten States with Highest Cancer Incidences (‘000), 2014
Table 4-2: Top Ten Cancer Incidences in Males (2014)
Table 4-3: Top Ten Cancer Incidences in Females (2014)
Table 5-1: Top Ten States with Households earning > US$ 100K (2012)
Table 5-2: Key Demographics and Potential Customers for Personalized Cancer WGS Market (2014)
Table 5-3: Potential States for Personalized Cancer Whole Genome Sequencing
Table 9-1: Illumina - Key information
Table 9-2: Complete Genomics - Key Information
Table 9-3: Beckman Coulter Genomics - Key Information
Table 9-4: Expression Analysis - Key Information
Table 9-5: Edge Bio - Key Information
Table 9-6: Foundation Medicine - Key Information
Table 9-7: SeqWright - Key Information
Table 9-8: Ambry Genetics - Key Information
Table 9-9: BGI Americas Corporation - Key Information
Table 9-10: Cofactor Genomics - Key Information
Table 4-1: Top Ten States with Highest Cancer Incidences (‘000), 2014
Table 4-2: Top Ten Cancer Incidences in Males (2014)
Table 4-3: Top Ten Cancer Incidences in Females (2014)
Table 5-1: Top Ten States with Households earning > US$ 100K (2012)
Table 5-2: Key Demographics and Potential Customers for Personalized Cancer WGS Market (2014)
Table 5-3: Potential States for Personalized Cancer Whole Genome Sequencing
Table 9-1: Illumina - Key information
Table 9-2: Complete Genomics - Key Information
Table 9-3: Beckman Coulter Genomics - Key Information
Table 9-4: Expression Analysis - Key Information
Table 9-5: Edge Bio - Key Information
Table 9-6: Foundation Medicine - Key Information
Table 9-7: SeqWright - Key Information
Table 9-8: Ambry Genetics - Key Information
Table 9-9: BGI Americas Corporation - Key Information
Table 9-10: Cofactor Genomics - Key Information
